TBOPP|cas:1996629-79-8|西域试剂

TBOPP,99.89%

产品编号：Bellancom-124711| CAS NO：1996629-79-8| 分子式：C₂₄H₂₁F₃N₂O₄S| 分子量：490.49

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-124711	￥4500.00	杭州北京（现货）
Bellancom-124711	￥7500.00	杭州北京（现货）
Bellancom-124711	￥0.00	杭州北京（现货）
Bellancom-124711	￥0.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

TBOPP

产品介绍

TBOPP 是一种 DOCK1 的选择性抑制剂，其 IC₅₀ 为 8.4 μM。TBOPP 以高亲和力 (K_d 为 7.1 μM) 与 DOCK1 DHR-2 结构域结合，对广泛类型的肿瘤均具有抗肿瘤活性。

生物活性

TBOPP is a selective inhibitor of DOCK1 with an IC₅₀ of 8.4 μM. TBOPP binds to the DOCK1 DHR-2 domain with high affinity (K_d of 7.1 μM), has anti-tumor activity for broader types of tumors.

体外研究

TBOPP (12.5 µM; 3 days; 3LL cells) treatment inhibits DOCK1-mediated invasion, macropinocytosis, and survival under the condition of glutamine deprivation without impairing the biological functions of the closely related DOCK2 and DOCK5 proteins.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	3LL cells
Concentration:	12.5 µM
Incubation Time:	3 days
Result:	Inhibited cell viability.

体内研究
(In Vivo)

TBOPP (0.67 mg per mouse; administrated on days 0, 1, 3, and 5; for 2 weeks; C57BL/6 mice) treatment effectively suppresses metastasis of cancer cells in vivo and the number of lymphocytes in the spleen is not changed, the body weight is also unchanged between TBOPP-treated and non-treated mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice (6- to 8-week-old) with ex-3LL cells
Dosage:	0.67 mg per mouse
Administration:	Administrated on days 0, 1, 3, and 5; for 2 weeks
Result:	The lung metastasis was significantly suppressed.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice (6- to 8-week-old) with ex-3LL cells
Dosage:	0.67 mg per mouse
Administration:	Administrated on days 0, 1, 3, and 5; for 2 weeks
Result:	The lung metastasis was significantly suppressed.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice (6- to 8-week-old) with ex-3LL cells
Dosage:	0.67 mg per mouse
Administration:	Administrated on days 0, 1, 3, and 5; for 2 weeks
Result:	The lung metastasis was significantly suppressed.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (203.88 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0388 mL	10.1939 mL	20.3878 mL
5 mM	0.4078 mL	2.0388 mL	4.0776 mL
10 mM	0.2039 mL	1.0194 mL	2.0388 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (4.24 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.24 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.24 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.24 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。